Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | RXRB | P28702 | 1/20 | 0.53 |
| ▸ | RXRG | P48443 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.39 |
| ▸ | TNKS | O95271 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 10/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL767226 | 0.89 | RXRA (0.55) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL767362 | 0.87 | RXRA (0.53) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL767345 | 0.87 | RXRA (0.51) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL767263 | 0.87 | RXRA (0.53) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL768079 | 0.87 | RXRA (0.53) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL768583 | 0.86 | RXRA (0.52) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL767097 | 0.86 | RXRA (0.52) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL767165 | 0.86 | RXRA (0.52) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL767409 | 0.85 | RXRA (0.52) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL766981 | 0.85 | RXRA (0.55) | RXRARXRBRXRGALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-9868704-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868704-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868704-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160297767-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160297767-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-9399646-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| EP-2735562-B1 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2015-03-11 | — | — | EP | disclosed |
| EP-2735562-B1 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20130012561-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012561-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8299112-B2 | Estrogen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299112-B2 | Estrogen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| WO-2012037411-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012037410-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012037410-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037411-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | RXRA 34/4885RXRB 38/4885RXRG 21/4885 |
| US-20130012561-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | RXRA 34/4885RXRB 38/4885RXRG 21/4885 |
| US-20160297767-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | RXRA 34/4885RXRB 38/4885RXRG 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.